我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
24
22 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
22
91.7%
已完成
2
8.3%
暂无批准数据
- Lexicon's SONATA-HCM Phase 3 trial evaluating sotagliflozin for hypertrophic cardiomyopathy is targeting enrollment completion in mid-2026 with topline results expected in Q1 2027. - The company remains on track for Zynquista NDA resubmission in 2026 based on FDA feedback and additional clinical data from the STENO1 study. - Lexicon triggered a $10 million milestone payment from Novo Nordisk for LX9851, an oral ACSL5 inhibitor for obesity, with potential for up to $950 million in remaining milestones. - The company ended 2025 with $125.2 million in cash, sufficient to support planned operations into 2027.
